Study of Pirtobrutinib (LOXO-305) in Participants With Impaired Liver Function and Healthy Participants

NCT06190691 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy
Hepatic Insufficiency

Interventions

DRUG: Pirtobrutinib

Sponsor

Eli Lilly and Company

Collaborators

[object Object]